all report title image
  • Published On : Jan 2023
  • Code : CMI102
  • Industry : Biotechnology
  • Pages : 222
  • Formats :

Chimeric antigen receptor (CAR)-T cell therapy is a type of gene cell therapy in which the T cells are used to kill the cancer cells. There are basically three steps involve in CAR T cell therapy which included: collecting of T cells, engineering of T cells, and infusing the CAR T cells in human body. Chimeric antigen receptor (CAR)-T cell therapy is a T cell immunotherapy in which body’s own immune system is utilized to fight cancer. Cytokine release syndrome (CRS) is a serious complication of CAR T cell therapy in which CAR T cell release chemicals called cytokines and cause reaction from the immune systems these reactions includes: Fever and chills, fatigue, nausea, diarrhea, low blood pressure, difficulty in breathing, and etc.

Global CAR T cell therapy market is estimated to be valued at US$ 2,259.5 million in 2022 and is expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030).

Figure 1.Global CAR T Cell Therapy Market Share (%), by Targeted Antigen, 2022

CAR T Cell Therapy  | Coherent Market Insights

Global CAR T Cell Therapy Market - Drivers

Increasing prevalence of cancer is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in February 2022, the World Health Organization (WHO) published a fact sheet according to which, every year around 400,000 children develop cancer and 2.26 million cases of breast cancer were found in 2021, globally.

Furthermore, key companies focusing on product approval is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in April, 2022, Kite Pharma, Inc., a subsidiary of Gilead Sciences, Inc., one of the research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, obtained the U.S. Food and Drug Administration approval for Yescarta for initial treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Figure 2.Global CAR T Cell Therapy Market Share (%), by Region, 2022

CAR T Cell Therapy  | Coherent Market Insights

Global CAR T Cell Therapy – Impact of Coronavirus (COVID-19) Pandemic:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to a November 2022 published World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 632,533,408 confirmed cases infected by COVID-19 worldwide as of 15 November 2022.

Furthermore, COVID-19 pandemic has a significance impact on cancer patients due to use of CAR-T cell therapy for SARS-CoV-2. For instance, in April 2020, a data published by Duke-NUS, a school of National University of Singapore according to which CAR-T cell therapy can be used for treatment of SARS-CoV-2 and other infectious disease.

Global CAR T Cell Therapy Market: Key Developments

In June 2022, Bristol-Myers Squibb Company, one of the global leader in Biopharmaceutical company, obtained the U.S. Food and Drug Administration (FDA), approval for Breyanzi CAR T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after one prior therapy. Approval was based on data from the Phase 2 pilot company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL.

In February, 2022, Johnson & Johnson Services, Inc., one of the largest healthcare company, announced that, the U.S. Food and Drug Administration approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.

CMI table icon

CAR T Cell Therapy Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,259.5 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 20.9% 2030 Value Projection: US$ 10,280.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Targeted Antigen: CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)
  • By Therapeutic Application: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)
Companies covered:

Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics 

Growth Drivers:
  • Increasing  CAR T cell therapy product launch 
  • Increasing prevalence of cancer
Restraints & Challenges:
  • Side effects associated with CAR T cell therapy

Global CAR T Cell Therapy Market: Restraint

The major factor that hinder growth of the global CAR T cell therapy market include the side effects of CAR T cell therapy. For instance, in March, 2022, American Cancer Society, a nationwide voluntary health organization, published a data according to which there are many possible side effects of CAR T cell therapy which includes: high fever and chill, trouble breathing, severe nausea, vomiting, and/or diarrhea, feeling dizzy or lightheaded, headaches, fast heartbeat, feeling very tired, muscle and/or joint pain etc.

Global CAR T Cell Therapy market- Key Players

Major players operating in the global CAR T cell therapy market include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells.  After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study:

  • This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global CAR T cell therapy  market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global CAR T cell therapy  market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market

Detailed Segmentation:

  • Global CAR T Cell Therapy  Market, By Targeted Antigen:
    • CD19
    • BCMA
    • HER2
    • GD2
    • CD20
    • CD22
    • CD30
    • CD33
    • HER1
    • Others (CLDN18, etc.)
  • Global CAR T Cell Therapy Market, By Therapeutic Application:
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Glioblastoma
    • Sarcoma
    • Neuroblastoma
    • Acute Myeloid Leukemia
    • Breast Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Colorectal Cancer
    • Others (Gastric Cancer, etc.)
  • Global CAR T Cell Therapy  Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bristol-Myers Squibb Company
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • CARsgenTherapeutics Co., Ltd
    • Aurora Biopharma
    • Legend Biotech
    • Gilead Sciences, Inc.
    • Pfizer Inc.
    • bluebird bio, Inc.
    • Sorrento Therapeutics, Inc.
    • Mustang Bio
    • Fate Therapeutics

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global CAR T cell therapy market size is estimated to be valued at US$ 2,259.5 million in 2022 and is expected to exhibit a CAGR of 20.9% between 2022 and 2030.
Increasing prevalence of cancer and increasing adoption of strategies like product launch, product approval by the key players are driving growth of the market.
CD19 is the leading targeted antigen segment in the market
The major factors hampering growth of the market include side effects associated with CAR T cell therapy.
Major players operating in the market  include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo